histocompatible siblings were identified. A matched unrelated donor (MUD) search found a compatible mixed lymphocyte reaction negative donor. A 40-year-old male with Ph-positive CML underwent PBSC autografting after initial treatment with hydroxCytogenetic and molecular analysis results are summarised in Table 1 . Cytogenetic examination of the marrow yurea and interferon. Following autograft he remained in chronic phase with cytogenetic or molecular evidence during 1990 and 1991 showed persistence of the Ph chromosome. Two samples identified an additional chromoof low levels of residual Ph-positive cells. However, additional cytogenetic abnormalities, including t(3;21) some 8 at a low level (7% and 3% of cells, respectively) which may have been present in the previous samples, and typically seen in therapy-related myelodysplastic syndrome (MDS) and AML and blast crisis of CML, was not considered necessarily to indicate disease prodeveloped as an independent cell line following the autograft. More than 4 years after the autograft, the patient remains in chronic phase with no evidence of accelerated phase or blast crisis of CML, but with a concurrent MDS. We report a case of CML who developed therapyrelated MDS following PBSC autograft while still remaining in chronic phase.
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der (20) a FISH using probes for 1p36 and 1qh, ie pE25.a (D1Z7) and p1-79 (D1Z2) (ATCC, Rockville MD, MD, USA). b FISH using whole chromosome specific paints for chromosomes 1, 3, 20, 21 (Cambio, Cambridge, UK) . c FISH using bcr and abl probes (Oncor) on metaphases and interphases. d FISH using bcr and abl probes (Vysis, Eastleigh, UK) on interphases only (normal control range 0-15%). e ND = not done. Molecular tests were not always carried out because of insufficient material, or in view of results obtained cytogenetically. idem = XY,t(9;22;10)(q34;q11;p11); PBSC = peripheral blood stem cells.
gression. Molecular studies using Southern blot DNA Engraftment was slow following transplantation. Cytogenetics on the marrow in September, October and November analysis of the April 1990 marrow confirmed the presence of a rearrangement of the major breakpoint cluster region 1992 did show the presence of the Ph chromosome in 22%, 6% and 4% of cells, respectively, suggesting a continuing (M-BCR) of the BCR gene on chromosome 22, consistent with a BCR/ABL gene fusion (TransProbe-1, Oncogene reduction in the size of the Ph clone. Molecular analysis on a blood sample also taken in November 1992, gave a Science, Uniondale, NY, USA).
In view of his age, it was decided not to proceed with a negative result on Southern blot DNA analysis for the M-BCR rearrangement, but a positive result with a single step MUD transplant but to treat with a PBSC autograft and the precursor cells were collected after treatment with daunoreverse transcriptase polymerase chain reaction (RT-PCR) analysis of the RNA. 7 This confirmed the continuing presrubicin, etoposide and cytosine arabinoside. Southern blot DNA analysis of a series of PBSC collections in late 1991 ence of a Ph clone at a low level. Additional cytogenetic findings (November 1992 marrow) were the presence of gave a mixture of negative and weakly positive results. The lower limit of sensitivity of this molecular technique is 5%.
several cells with single cell abnormalities and a substantial new abnormal clone with t(1;15) and t(19;20) transloFour months after PBSC collection a marrow sample again demonstrated rearrangement within the M-BCR region on cations, none of which have been seen again in subsequent samples. chromosome 22. Concurrent cytogenetic analysis showed a reduction in the size of the Ph clone from 100 to 32%.
A marrow in January 1993 showed no cytogenetic evidence of the Ph clone, but molecular tests for minimal He underwent a PBSC autograft in July 1992 after conditioning with fractionated total body irradiation (14.4 Gy) residual disease failed. However, the cytogenetic analysis did show yet another new clonal abnormality in all the cells and cyclophosphamide (120 mg/kg body weight).
involving chromosomes 1, 3, 20 and 21 (Figure 1 ). It was chromosomal abnormalities and secondary malignancies are known to occur after chemotherapy. Recently the not possible to characterise fully the rearrangements on this sample and therefore their significance was not immediately t(3;21) rearrangement as a recurring chromosomal abnormality has been described in therapy-related myelodysplasrealised. The same abnormal cell line was seen in subsequent blood samples in March, June and September 1993.
tic syndrome (tMDS) and acute myeloid leukaemia (tAML). 1, 2 The AML1 gene located on band q22 of chromoThe continuing presence of the Ph clone at a low level was indicated by Southern blot DNA analysis of the March some 21 has been shown to be usually rearranged with the EAP gene, but sometimes the EVI1 gene, or MDS1 gene sample, and a single Ph-positive metaphase on one of the September samples. However, single step RT-PCR analysis on chromosome 3 resulting in fusion transcripts. 3, 4 Similar t(3; 21) abnormalities are known to occur in blast crisis during the same period on samples in July and September produced negative results, a discrepancy which may be due (BC) of CML. 2, 5 A rearrangement involving the AML1 gene on chromosome 21 can also occur in de novo AML subtype to the poor quality of the RNA extracted. The cytogenetic results also indicated the continuing presence of a normal M2 where translocation between chromosomes 8 and 21 is reported in 40% of patients. However, the breakpoint of cell line.
In September 1993, 14 months after transplantation the the rearrangement in AML M2 has been shown to be different from that in tAML/tMDS and BC-CML although still patients' ferritin level was found to be high at 6990 g/l and he was started on iron chelation therapy. Following the involving the AML1 gene. 2 Breakpoints in band 3q26 also feature in a number of different rearrangements involved autograft bone marrow reconstitution was incomplete with moderate pancytopenia. A full blood count in early 1994 in haematological malignancies. These are always myeloid disorders, usually with trilineage myelodysplasia and showed WCC 3.0 × 10 9 /l, Hb 9.8 g/dl, MCV 92 and platelets 84 × 10 9 /l. In view of the low haemoglobin he was abnormal megakaryopoiesis with micromegakaryocytes. The cases with 3q abnormalities are usually found to be started on erythropoietin (EPO) This confirms that the abnormal cell line has evolved independent of the original Ph-positive CML cell line, suggestIn November 1994 cytogenetics showed both a normal cell line and the complex karyotype with rearrangements ing a therapy-related MDS developing in this patient. This is supported by the clinical observation that the patient involving chromosomes 1, 3, 20 and 21 that had previously been observed since January 1993. Using fluorescent in situ remains in chronic phase more than 4 years (54 months) after the detection of this abnormality. The t(3;21) in tMDS hybridisation techniques (FISH) this was shown to include a rearrangement of chromosomes 1 and 20 resulting in a and tAML has been reported to be particularly associated with previous therapy with drugs, such as epipodophylloderived chromosome 20 from an unbalanced t(1;20) translocation with loss of the long arm of one chromosome 20 toxins and anthracyclines that target DNA-topoisomerase II. 9,10 Our case is consistent with this observation. and possible loss of part of the short arm of one chromosome 1; and a translocation between the long arms of one
The significance of the Ph-negative transient abnormal clones and single cell abnormalities seen in our patient 4 of each of chromosomes 3 and 21. There were no cells with a Ph chromosome. Further FISH studies using probes months after autograft, and the further transient clone seen 36 months after autograft, is uncertain. Possible transient specific for the ABL gene on chromosome 9 and the BCR gene on chromosome 22 (Oncor, Gaithersburg, MD, USA) clones and single cell abnormalities have been documented post-allograft BMT in CML [11] [12] [13] and post-autologous transconfirmed that there were no sub-microscopic M-BCR/ABL rearrangements consistent with CML in the complex cell plants in other leukaemias. [14] [15] [16] They are considered likely to be the consequence of chromosome damage due to conline with the t(3;21).
Cytogenetics on blood and marrow samples from July ditioning regimens, post-transplant viral infections and related therapies. [11] [12] [13] When these abnormalities are transi-1995 to October 1996 showed the continuing presence of both the normal and t(3;21) cell lines, and the re-emergence ent they appear to have no clinical effect. However, stable clones have also been reported 16, 17 and in these cases the of the Ph clone. Currently the patient remains on IFN 3 mega units three times a week with WCC 2.6 × 10 9 /l, Hb prognosis is uncertain. 
